|
|
Protein profiling by RPMA technology
The NMI TT GmbH offers protein profiling services for the analysis of protein expression in extremely small samples
using the Reverse Phase Protein Micro Array (RPMA) platform. RPMA is
used for biomarker research, screening in early drug discovery, in
preclinical development and in clinical research.
The technology is based on specific immunoassays (analogous to the Western Blot) and allows the parallel analysis of dozens
of analytes in hundreds of samples, with a throughput of up to 10,000 Western Blot lanes per day.
We offer:
- multiplexed analysis of differential protein expression and signaling pathway mapping
- screening of phosphoprotein activation and inhibition
- effect of drug candidates on cellular proteins in cell cultures (drug profiling, IC50)
- biomarker screening for preclinical drug discovery (analysis of
samples from cell culture studies and from tissues of animal studies),
and for clinical studies (analysis of tissue biopsies, e.g. tumors)
| print |
|
top |
|
NMI TT GmbH Markwiesenstr. 55 D-72770 Reutlingen
Tel: +49 7121 51530-0 info@nmi-tt.de |
|
|
|
Contact person Dr. Michael Pawlak
E-mail:michael.pawlak(at)
nmi.de
Phone: +49(0)7121 51530 13
|
|
|